BLA 103770 · Swedish Orphan
Synagis
Palivizumab
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: May 12, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Jun 19, 1998
Approved uses
3
Original approval plus efficacy supplements
Registered trials
19
8 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 4, 2012 Supplement 5161 · Efficacy LetterLabel
- Sep 15, 2003 Supplement 5033 · Efficacy Review
- Jun 19, 1998 Original approval · Type 1 - New Molecular Entity · priority review ReviewLetter
2 products under this application
- SYNAGIS · PALIVIZUMAB 100MG/VIAL · VIAL, · Prescription
- SYNAGIS · PALIVIZUMAB 50MG/VIAL · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Palivizumab" as an intervention, any sponsor and status, largest first.
- Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk ChildrenPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT00129766 · 6,635 participants · Start Nov 2004 · Primary completion May 2006
Drug: motavizumab (MEDI-524); palivizumab · For: Respiratory Syncytial Virus Infections
Sites: Birmingham, Alabama; Pike Road, Alabama; Phoenix, Arizona · 344 sites in all
- A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart DiseasePivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT00538785 · 1,236 participants · Start Oct 2005 · Primary completion Jun 2008
Drug: Motavizumab; Palivizumab · For: Congenital Heart Disease
Sites: Little Rock, Arkansas; Long Beach, California; Los Angeles, California · 152 sites in all
- Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04938830 · 1,003 participants · Start Nov 30, 2021 · Primary completion Apr 28, 2025
Drug: Clesrovimab; Palivizumab and 1 more · For: RSV Infection
Sites: Long Beach, California; Orange, California; Aurora, Colorado · 146 sites in all
- A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk ChildrenPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT03959488 · 925 participants · Start Jul 30, 2019 · Primary completion May 3, 2021
Drug: MEDI8897; Palivizumab · For: Respiratory Syncytial Virus Infections
Sites: Anaheim, California; Long Beach, California; Los Angeles, California · 128 sites in all
- "Palivizumab Therapy for RSV-bronchiolitis"Pivotal-lookingCompleted
Hamad Medical CorporationIndustry
NCT02442427 · 420 participants (planned) · Start Sep 2014 · Primary completion Feb 1, 2018
Drug: Palivizumab · For: Respiratory Syncytial Virus-bronchiolitis
Sites: Doha, Qatar
- Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)Pivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT00233064 · 417 participants · Start Oct 2005 · Primary completion Oct 2007
Drug: Lyophilized Palivizumab; Liquid Palivizumab · For: Chronic Lung Disease
Sites: Birmingham, Alabama; Hoover, Alabama; Tuscaloosa, Alabama · 54 sites in all
- Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) SeasonPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT00316264 · 260 participants · Start Apr 2006 · Primary completion Feb 2007
Drug: Motavizumab, palivizumab; Palivizumab, motavizumab and 1 more · For: Respiratory Syncytial Virus Infections; Chronic Lung Disease and <= 24 Months of Age or; Premature With Gestational Age <=35 Weeks and <=6 Months of Age
Sites: Garran, Australia; New Lambton Heights, Australia; Caboolture, Australia · 19 sites in all
- A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)Pivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT00240929 · 150 participants · Start Sep 2002
Drug: MEDI-493 · For: -Unhealthy Children With a History of Prematurity
Sites: Palo Alto, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.
Wilkins D, Wählby Hamrén U, Chang Y, et al. · Pediatrics 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Bronchiolitis.
Bourke T, Shields M · BMJ Clin Evid 2011 · Systematic Review
- Bronchiolitis.
Lozano JM · BMJ Clin Evid 2007 · Systematic Review
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
Garegnani L, Styrmisdóttir L, Roson Rodriguez P, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
Sun M, Lai H, Na F, et al. · JAMA Netw Open 2023 · Systematic Review, Network Meta-Analysis
- RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.
Oliva IO, Oliveira CR · Hum Vaccin Immunother 2026 · Meta-Analysis, Review
Sponsor: Swedish Orphan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.